A simple stomach infection may seem like a minor problem, but for millions of children around the world it can become a life-threatening illness.
Severe diarrhea remains one of the leading causes of sickness and death among young children in many developing countries.
Because of this, scientists have spent decades searching for better ways to prevent these infections before they start.
Researchers led by the University of Bergen have now taken an important step toward that goal. Their newly developed vaccine technology has been licensed to the vaccine company Valneva, which will take over the next stages of development.
The announcement does not mean a vaccine is ready yet, but it shows that experts believe the research has strong potential.
The technology targets enterotoxigenic Escherichia coli, better known as ETEC. This bacterium spreads mainly through contaminated food and drinking water. After entering the body, it releases toxins that cause severe watery diarrhea.
While healthy adults often recover, repeated infections can seriously harm babies and young children by causing dehydration, poor nutrition and slower physical development.
The research was carried out through an international partnership involving the University of Bergen, NORCE, Institut Pasteur, the Indian Institute of Science, Tulane University and South Dakota State University. Scientists have been studying ETEC in Bergen since the 1980s, showing how long vaccine development can take.
One of the biggest scientific challenges has been a toxin known as STh. Because it is extremely small and behaves differently from many other disease-causing molecules, it has been very difficult to include safely in a vaccine. Rather than giving up, the researchers gradually improved their designs over many years until they produced a technology that attracted commercial interest.
Valneva will now continue the work by investing in the expensive process needed to turn laboratory discoveries into a real vaccine. The agreement also includes plans that may help ensure future access for low- and middle-income countries, where ETEC causes the greatest burden of disease.
If successful, the vaccine could have benefits beyond preventing diarrhea. Fewer infections would mean fewer hospital admissions, lower healthcare costs, improved childhood growth and development, and less need for antibiotics. Reducing antibiotic use is especially important because antibiotic resistance is becoming a growing global health problem.
Even so, people should understand that vaccine development takes time. Many promising vaccine candidates never reach the market because they fail during safety or effectiveness testing. Clinical trials involving volunteers will be needed before doctors know whether this vaccine provides strong protection.
The licensing agreement represents confidence in the science, not the final proof that the vaccine works. Still, it is an encouraging sign because companies generally invest only when they believe a technology has realistic potential.
Study review and analysis: This work demonstrates the value of long-term scientific collaboration and persistence. Instead of reporting clinical results, it describes a successful transition from university research to commercial development.
The main limitation is that no human trial results are yet available. Nevertheless, the technology addresses an important unmet medical need and could eventually improve child health in many countries if future testing is successful.
If you care about health, please read studies that vitamin D could help lower the risk of autoimmune diseases, and drug for inflammation may stop spread of cancer.
For more health information, please see recent studies about which drug can harm your liver most, and results showing this drug can give your immune system a double boost against cancer
Source: University of Bergen.
